Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Second generation direct acting antivirals (DAAs) drastically changed the landscape of chronic HCV (CHCV). Aim of this paper was to assess the effectiveness of DAAs, also looking at the demographic characteristics of subjects enrolled.
Research Design And Methods: Ambispective multi-center real-life study conducted among patients with CHCV treated with DAAs in Campania Region (Southern Italy). Patient were enrolled in two cohorts according to time of enrolment.
Results: 1,479 patients were enrolled. Patients aged ≥60 years were 74.7% in the historic cohort (953 patients) and 70.2% in the prospective cohort (526 patients. Patients aged ≥ 60 years showed a higher prevalence of genotype 1b (p<0.001) and 2 (p<0.001), while patients aged < 60 years showed a higher prevalence of genotype 1a (p<0.001), 3 (p<0.001) and 4 (p<0.05). SVR12 was 98.5% in both cohorts. SVR12 was similar among patients of the prospective cohort aged < and ≥ 60 years (99.4% vs 98.1%). SVR12 among patients with and without cirrhosis was 96.0% and 98.9%, respectively.
Conclusions: DAAs provide high efficacy also in harder to treat patients. The effectiveness of DAAs is leading to a shift in patients characteristics with a greater prevalence of younger subjects and persons with mild liver disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17474124.2021.1890029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Maturational Changes in Action-Effect Integration Processes Are Reflected by Changes in the Directed Cortical Network Communication.
Hum Brain Mapp
September 2025
Cognitive Neurophysiology, Department of Child and Adolescent Psychiatry, Faculty of Medicine, TU Dresden, Dresden, Germany.
Acting intentionally is a major aspect of human cognitive development and depends on the ability to link actions with their consequences. Action-effect binding (AEB) is a fundamental mechanism enabling this. While AEB has been well-characterized in adults, its neurophysiological underpinnings during adolescence remain unclear.
View Article and Find Full Text PDFResearch progress on bioactive peptides in the treatment of oral diseases.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Maxillofacial Surgery, Xiangya Hospital of Stomatology, Central South University, Changsha 410013, China.
Peptide-based drugs possess several advantages, including high specificity, low immunogenicity, minimal accumulation, and fewer drug-drug interactions, making them a novel and efficient therapeutic class for various diseases. In recent years, peptide-based drugs have shown great potential and broad application prospects in the treatment of oral infectious diseases, tissue injury and repair, tumors, and complex oral mucosal disorders, acting either through direct mechanisms or indirect modulation. Oral administration remains the preferred route due to its non-invasive, painless nature and ease of management; however, gastrointestinal pH can inactivate or even degrade peptide drugs.
View Article and Find Full Text PDFPredicting Treatment Response in Retinal Vein Occlusions Using Baseline Optical Coherence Tomography Biomarkers: A Systematic Review.
Surv Ophthalmol
September 2025
Department of Surgery, Division of Ophthalmology, McMaster University, Hamilton, Ontario, Canada; Singapore Eye Research Institute, Singapore National Eye Center, Singapore. Electronic address:
This systematic review examines the prognostic value of baseline optical coherence tomography (OCT) biomarkers in predicting visual acuity (VA) outcomes for eyes with macular edema secondary to retinal vein occlusions (RVO) treated with anti-VEGF therapies, steroids, laser photocoagulation, or combination treatments. VA predictions at 6, 12, and 24 months post-treatment were assessed using a narrative synthesis approach and vote counting based on effect direction relative to a minimal clinically important difference. Certainty of evidence was evaluated using GRADE guidelines.
View Article and Find Full Text PDFTrends in Use of Direct-Acting Antivirals for Treatment of Hepatitis C Virus Infection in Australia 2016-2024.
J Viral Hepat
October 2025
Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment in Australia since their inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2016. Treatment has shifted from genotype-specific to pan-genotypic regimens, with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir now recommended in clinical guidelines. This study examined trends in DAA dispensing in light of evolving treatment regimens.
View Article and Find Full Text PDF[Representation of infectious risk in patients with multiple myeloma: A multicentric prospective study aimed at adapting the role of advanced practice nurses].
Bull Cancer
September 2025
Direction des soins, centre hospitalier de Brive, 2, boulevard du Dr-Verlhac, 19100 Brive, France. Electronic address:
Multiple myeloma is a haematologic malignancy of the bone marrow with an increasing incidence, primarily affecting an elderly and frail population. It benefits from innovative treatments that have been shown to extend patient survival. However, 2% of patients die from infections during the first year of treatment, despite the availability of prophylactic treatments.
View Article and Find Full Text PDF